Use of Kidneys with Small Renal Tumors for Transplantation

Current Urology Reports

Volumn 17, Issue 1, 2016, Pages 1-7

  Lugo Baruqui, Alejandro ^a   Guerra, Giselle ^a   Arocha, Adriana ^a   Burke, George W ^a   Ciancio, Gaetano ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Deceased donors; End stage renal disease; Kidney transplant; Kidney tumor; Living donors; Renal cell carcinoma

Indexed keywords

CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; END STAGE RENAL DISEASE; GRAFT RECIPIENT; HOSPITAL ADMISSION; HUMAN; KIDNEY CARCINOMA; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; NEPHRECTOMY; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK FACTOR; CADAVER; CARCINOMA, RENAL CELL; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; LIVING DONOR;

CADAVER; CARCINOMA, RENAL CELL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; LIVING DONORS;

EID: 84951153827     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0557-z     Document Type: Review

References (39)

1. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(1):S1–306.
2. Bouaoun L, Villar E, Ecochard R, Couchoud C. Excess risk of death increases with time from first dialysis for patients on the waiting list: implications for renal allograft allocation policy. Nephron Clin Pract. 2013;124(1–2):99–105.
3. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS One. 2012;7(1), e29591.
4. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.
5. U.S. Department of Health & Human Services, Organ Procurement and Transplantation Network, http://optn.transplant.hrsa.gov/, Accessed on august 11th, 20015
6. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001;12(3):589–97. Authors demonstrate a survival benefit of patients receiving a marginal kidney graft as compared to remain on the waiting list.
7. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg. 2014;101(7):768–74.
8. Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant. 2013;13(10):2645–52. Excellent review of the available data on donor cancer transmission among kidney transplant recipients with cancer free survivals.
9. Patard JJ. Incidental renal tumours. Curr Opin Urol. 2009;19(5):454–8.
10. Violette P, Abourbih S, Szymanski KM, Tanguay S, Aprikian A, Matthews K, et al. Solitary solid renal mass: can we predict malignancy? BJU Int. 2012;110(11 Pt B):E548–52.
11. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014 Nov 10;349:g4797. Comprehensive review of the surgical management and systemic te¿reatment of renal cell carcinoma.
12. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
13. Motzer RJ, Agarwal N, Beard C, et al. Kidney cancer. J Natl Compr Cancer Netw. 2011;9:960–77.
14. Cohen HT, McGovern FJ. Renal-cellcarcinoma. N Engl J Med. 2005;353(23):2477–90.
15. Edge S, Bird DR, Compton CC, Fritz AG, Greene, FL, Trotti A, eds. Kidney. In: American Joint Committee on Cancer Staging manual. 7th ed. Springer, 2010.
16. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52. Prospective stury that demonstrates similar comparative results in patients with small renal cell carcinoma treated with nephron sparing surgery vs radical nephrectomy.
17. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. 2014. v.3
18. Bex A, Larkin J, Voss M. Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies. Am Soc Clin Oncol Educ Book. 2015;35:e239–47.
19. van Oostenbrugge TJ, Kroeze SG, Bosch JL, van Melick HH. The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol. 2015;33(6):881–7.
20. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. Kidney cancer, version 3.2015. Featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2015;13(2):151–9.
21. Buell JF, Hanaway MJ, Thomas M, Munda R, Alloway RR, First MR, et al. Donor kidneys with small renal cell cancers: can they be transplanted? Transplant Proc. 2005;37(2):581–2. First report to address the use of kidneys with small, incidental renal cell carcinoma with excision and transplantation.
22. Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, et al. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. BJU Int. 2008;102(2):188–92. Largest series of kidney transplants with incidental renal cell carcinoma from living and deceased donors.
23. Musquera M, Pérez M, Peri L, Esforzado N, Sebastià MC, Paredes D, et al. Kidneys from donors with incidental renal tumors: should they be considered acceptable option for transplantation? Transplantation. 2013;95(9):1129–33. Part of the literature evidence on the use of incidental renal cell carcinoma for transplantation with very complete description of induction immunosuppression and complications.
24. Brook NR, Gibbons N, Johnson DW, Nicol DL. Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. Transpl Int. 2010;23(5):476–83. Extension of the follow upperiod from the serioes of patients reported by Nicol et al. with atient survival at 5 years of 88 % for recipients of tumourectomized kidneys.
25. Sener A, Uberoi V, Bartlett ST, Kramer AC, Phelan MW. Living-donor renal transplantation of grafts with incidental renal masses after ex-vivo partial nephrectomy. BJU Int. 2009;104(11):1655–60. Report on the use of incidental finding of renal cell carcinoma in living donors with suggested radiological follow up.
26. Mannami M, Mannami R, Mitsuhata N, Nishi M, Tsutsumi Y, Nanba K, et al. Last resort for renal transplant recipients, ‘restored kidneys’ from living donors/patients. Am J Transplant. 2008;8(4):811–8. Report on the use of kidneys with renall cell carcinomas, ureteral tumors and other abnormalities with 10 year graft survival of 42 % but no recurrences of malignancy.
27. Lugo-Baruqui JA, Guerra G, Chen L, Burke GW, Gaite JA, Ciancio G. Living donor renal transplantation with incidental renal cell carcinoma from donor allograft. Transpl Int. 2015 Apr 20. Report on the use of partial nephrectomy on the back table for kidneys with incidental renal cell carcinoma in living donors and follow up without recurrence.
28. Notify Group. NOTIFY. Exploring Vigilance Notification for Organs, Tissues and Cells. Bologna: Editrice compositori, 2011
29. Yu N, Fu S, Fu Z, Meng J, Xu Z, Wang B, et al. Allotransplanting donor kidneys after resection of a small renal cancer or contralateral healthy kidneys from cadaveric donors with unilateral renal cancer: a systematic review. Clin Transpl. 2014;28(1):8–15.
30. Rabbani F, Herr HW, Almahmeed T, Russo P. Temporal change in risk of metachronous contralateral renal cell carcinoma: Influence of tumor characteristics and demographic factors. J Clin Oncol. 2002;20:2370–5.
31. Wiklund F, Tretli S, Choueiri TK, et al. Risk of bilateral renal cell cancer. J Clin Oncol. 2009;27:3737–41.
32. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol. 2013;190(2):407–16.
33. Kreshover JE, Richstone L, Kavoussi LR. Renal cell recurrence for T1 tumors after laparoscopic partial nephrectomy. J Endourol. 2013;27(12):1468–70.
34. Stewart SB, Thompson RH, Psutka SP, Cheville JC, Lohse CM, Boorjian SA, et al. Evaluation of the national comprehensive cancer network and american urological association renal cell carcinoma surveillance guidelines. J Clin Oncol. 2014;32(36):4059–65. Guidelines for surveillance after surgery for renal cell carcinoma (RCC).
35. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;22 Suppl 1:i4–10.
36. Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transpl. 2014;28(6):635–48. Review on the use of m-Tor as immunosuppressive and antitumoral agent and the incidence of post-transplant malignancies with their use.
37. Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al. Maller ES; sirolimus CONVERT trial study group lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92(3):303–10. Study that reports the malignancy rates in renal allograft recipients at 2 years after conversion to a sirolimus based maintenance immunosuppression with lower malignancy rates specially in non-melanoma skin cancer.
38. SMART-Study Group, Guba M, Pratschke J, Hugo C, Krämer BK, Pascher A, et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transpl Int. 2012;25(4):416–23.
39. Flechner SM, Campbell SC. The use of kidneys with small renal tumors for transplantation: who is taking the risk? Am J Transplant. 2012;12(1):48–54. Paper with ethical considerations on the use of kindeys from living donors with incidental masses and recommendations on the management of the donor and recipients.